The impact of the codelivery of drug-siRNA by trimethy efficacy of chemotherapy for metastatic breast cancer c

Artificial Cells, Nanomedicine and Biotechnology

45, 889-896

DOI: 10.1080/21691401.2016.1185727

Citation Report

#	Article	IF	Citations
1	Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 1612-1619.	1.9	19
2	Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer. Immunology Letters, 2017, 181, 79-86.	1.1	87
3	Multifaceted Applications of Chitosan in Cancer Drug Delivery and Therapy. Marine Drugs, 2017, 15, 96.	2.2	100
4	Post-transcriptional suppression of TIMP-1 in epithelial-differentiated adipose-derived stem cells seeded bladder acellular matrix grafts reduces urethral scar formation. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 306-313.	1.9	9
5	Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 616-628.	1.9	42
6	Epigenetic Contribution of High-Mobility Group A Proteins to Stem Cell Properties. International Journal of Cell Biology, 2018, 2018, 1-20.	1.0	9
7	Natural Polysaccharides for siRNA Delivery: Nanocarriers Based on Chitosan, Hyaluronic Acid, and Their Derivatives. Molecules, 2019, 24, 2570.	1.7	89
8	Chitosan Derivatives and Grafted Adjuncts with Unique Properties. Biologically-inspired Systems, 2019, , 95-151.	0.4	5
9	Chitin/Chitosan: Versatile Ecological, Industrial, and Biomedical Applications. Biologically-inspired Systems, 2019, , 541-624.	0.4	15
10	Synergistically enhanced anticancer effect of codelivered curcumin and siPlk1 by stimuli-responsive Î±-lactalbumin nanospheres. Nanomedicine, 2019, 14, 595-612.	1.7	15
11	Effects of HMGA2 gene downregulation by siRNA on lung carcinoma cell migration in A549 cell lines. Journal of Cellular Biochemistry, 2019, 120, 5024-5032.	1.2	10
12	Blockage of immune checkpoint molecules increases Tâ€cell priming potential of dendritic cell vaccine. Immunology, 2020, 159, 75-87.	2.0	67
13	Targeting the intrinsically disordered architectural High Mobility Group A (HMGA) oncoproteins in breast cancer: learning from the past to design future strategies. Expert Opinion on Therapeutic Targets, 2020, 24, 953-969.	1.5	7
14	Silencing of HIF-1Î±/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. European Journal of Pharmacology, 2020, 882, 173235.	1.7	48
15	Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy. Carbohydrate Polymers, 2021, 260, 117809.	5.1	103
16	Expression of PLAG1, HMGA1 and HMGA2 in minor salivary glands tumours. Gland Surgery, 2021, 10, 1609-1617.	0.5	1
17	Clinicopathological characteristics and prognostic risk factors of breast cancer patients with bone metastasis. Annals of Translational Medicine, 2021, 9, 1340-1340.	0.7	6
18	PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD). Advanced Pharmaceutical Bulletin, 2020, 10, 502-511.	0.6	15

#	Article	IF	Citations
19	Nanoparticles as Therapeutic Delivery Systems in Relation to Cancer Diagnosis and Therapy. Current Nanoscience, 2019, 15, 218-233.	0.7	1
20	Chitosan: A versatile bio-platform for breast cancer theranostics. Journal of Controlled Release, 2022, 341, 733-752.	4.8	38
21	RNAi-based therapeutics and tumor targeted delivery in cancer. Advanced Drug Delivery Reviews, 2022, 182, 114113.	6.6	123
22	Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model. SSRN Electronic Journal, 0, , .	0.4	0
24	New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100103.	1.7	12
26	Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. Expert Opinion on Therapeutic Targets, 2022, 26, 513-535.	1.5	6
27	Nucleic Acid and Drug Dual Agent Nanoplatforms for Breast Cancer. , 2022, , .		0
28	Chitosanâ€based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy. Bioengineering and Translational Medicine, 2023, 8, .	3.9	32
29	Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses. Life Sciences, 2022, 309, 121008.	2.0	2
30	Update on modified chitosan frameworks and their applications for food, wastewater, toxic heavy metals, dyes treatment and cancer drug delivery. Journal of Environmental Chemical Engineering, 2022, 10, 108656.	3.3	8
31	Oral delivery of RNAi for cancer therapy. Cancer and Metastasis Reviews, 2023, 42, 699-724.	2.7	6